Hollis-Eden Pharmaceuticals to Present At Roth Capital Partners and BIO CEO Investor Conferences.Business Editors & Health/Medical Writers BIOWIRE2K SAN DIEGO--(BW HealthWire)--Feb. 19, 2002 Hollis-Eden Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :HEPH) today announced that it will present at the 14th Annual Roth Capital Partners Roth Capital Partners, LLC, is a full service Investment Banking firm, specializing in the small and micro cap markets. Roth’s focus, according to its official website, "has been, is, and will continue to be providing the full spectrum of investment banking services, Growth Stock Conference 2002 being held at The Ritz-Carlton, Laguna Niguel, February 18-20, 2002 and at the BIO CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and Investor Conference 2002 being held February 20-22 at the Waldorf-Astoria in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . Daniel Burgess, Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. and Chief Financial Officer of Hollis-Eden will present at the Roth Capital Partners Conference while Richard Hollis, Chairman and Chief Executive Officer will present at the BIO CEO and Investor Conference. There will be a live Webcast of the presentation from the conferences. Investors may access the audio Webcast with slide materials on the Investor Relations section of the Hollis-Eden website at www.holliseden.com. Daniel Burgess is scheduled to speak at 11:30 am eastern standard time Wednesday February 20th and Richard Hollis is scheduled to speak at 2:00 pm eastern standard time Thursday February 21st. Hollis-Eden Pharmaceuticals, Inc. is a development-stage pharmaceutical company based in San Diego, California “San Diego” redirects here. For other uses, see San Diego (disambiguation). San Diego is a coastal Southern California city located in the southwestern corner of the continental United States. As of 2006, the city has a population of 1,256,951. , engaged in the development of products for the treatment of infectious diseases and immune systems disorders. The Company's vision is to become the world leader in immune regulating hormones and their application to numerous diseases. The Company's lead investigational drug HE2000 is currently being studied in clinical trials for HIV/AIDS in South Africa HIV and AIDS in South Africa are a major health concern, and around 5.5 million people are thought to be living with the virus in South Africa. [1] HIV (human immunodeficiency virus) is the retrovirus that causes the disease known as AIDS (Acquired Immunodeficiency . In addition, Hollis-Eden is also conducting a Phase I/II clinical trial with HE2000 in the United States in HIV infected patients failing at least their second antiviral drug regimen. Phase II studies in Thailand are also being conducted with HE2000 in the treatment of malaria, and in Singapore for the treatment of hepatitis B. The Company is also conducting a Phase I clinical trial Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I in the United States with another of its immune regulating hormones, HE2200. In addition, through its relationship with Aeson Therapeutics, the Company also has access to HE2500, which is in Phase II clinical trials in cardiovascular disease and actinic keratosis. For more information on Hollis-Eden, contact the Company's website at www.holliseden.com. Statements made in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to successfully complete clinical trials, the Company's future capital needs, the Company's ability to obtain additional funding and required regulatory approvals, the development of competitive products by other companies, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion